

No. 81 / 9 October 2025

**To: BUCHAREST STOCK EXCHANGE
FINANCIAL SUPERVISORY AUTHORITY**

CURRENT REPORT

Current report drafted according to the stipulations of ASF Regulation no. 5/2018 on issuers of financial instruments and market operations, Law no. 24/2017 on issuers of financial instruments and market operations (republished), and the provisions of Article 99 of the Bucharest Stock Exchange Code, Title II, Issuers and Financial Instruments

Report Date: **9 October 2025**

Name of the issuing company: **MED LIFE S.A. ("MedLife" or "the Company")**

Registered Office: **Bucharest, 365 Calea Grivitei, district 1, Romania**

Telephone / Fax number: **0374 180 470**

Unique Registration Code at the National Office of Trade Registry: **8422035**

Order number on the Trade Registry: **J1996003709402**

EUID: **ROONRC.J1996003709402**

Subscribed and paid-in share capital: **RON 132,870,492**

Total number of shares: **531,481,968 (out of which 665,983 shares without voting rights and 530,815,985 shares with voting rights)**

Regulated market on which the issued securities are traded: **Bucharest Stock Exchange, Premium Category**

Significant events to report:

Closed trading period: 15 October – 13 November 2025

MED LIFE S.A. informs investors that between 15 October – 13 November 2025, the persons who have access to privileged information („insiders”) according to the provisions of FSA Regulation no. 5/2018, Law no. 24/2017 and EU Regulations no. 522/2016 and no. 596/2014 respectively, do not have the right to carry out any transactions in their own name or on behalf of a third party, directly or indirectly, related to shares, bonds, securities, debt or other derivative financial instruments of the Company.

This closed trading period occurs as a result of the fact that on 14 November 2025, the Company will publish the Q3 2025 Results Report.

Mihail Marcu
Chief Executive Officer